NCT03207347: A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
- State
- Completed
- Phase
- Phase 2
- People
- 37 taking part
- Started
- 13 Aug 2018
- Primary completion
- 30 Aug 2022
- Arms
- Cohort A, Cohort B
- Results
- Posted on the registry
- Papers
- doi:10.1200/po-24-00406
- 2 Jul 2017: Trial registered
- 13 Aug 2018: Trial started
- 30 Aug 2022: Trial completed
- 15 Sep 2023: Trial results posted